News
4hon MSN
James Van Der Beek is sharing the subtle colorectal cancer symptom he ignored before his shocking diagnosis. “There wasn’t ...
Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.
Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...
Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.
8d
PRIMETIMER on MSNGuardant Health joins forces with James Van Der Beek to raise colorectal cancer awarenessGuardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...
Van Der Beek first revealed he had colorectal cancer in a November interview with People, sharing he was diagnosed in August 2023. He says his cancer was detected via colonoscopy. Now, he's partnering ...
StockStory.org on MSN7d
Guardant Health (NASDAQ:GH) Beats Expectations in Strong Q2, Guides for Strong Full-Year SalesDiagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...
James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the ...
HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...
Guardant Health thinks around 700,000 patients in the U.S. could eventually benefit from advanced-stage cancer screening, which would drive up sales to around $6 billion annually.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results